In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions

Antimicrob Agents Chemother. 2018 Mar 27;62(4):e01971-17. doi: 10.1128/AAC.01971-17. Print 2018 Apr.

Abstract

Lascufloxacin showed potent activity against Streptococcus pneumoniae with a GyrA or ParC mutation (first-step mutant). The frequency of selecting resistant strains tended to be lower for lascufloxacin than for levofloxacin and garenoxacin after drug exposure in first-step mutants but was similar in the comparison between lascufloxacin and moxifloxacin. The increase in MIC was smaller for lascufloxacin than for levofloxacin, garenoxacin, and moxifloxacin when clinical strains with only ParC mutations were exposed to the corresponding drug.

Keywords: Streptococcus pneumoniae; fluoroquinolone resistance; lascufloxacin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Resistance, Bacterial / genetics
  • Fluoroquinolones / pharmacology*
  • Levofloxacin / pharmacology
  • Microbial Sensitivity Tests
  • Mutation / genetics
  • Quinolones / pharmacology*
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / genetics*

Substances

  • Fluoroquinolones
  • Quinolones
  • lascufloxacin
  • Levofloxacin
  • garenoxacin